This medicine is authorised for use in the European Union.


Trulicity is a medicine used in adults and children from 10 years of age with type 2 diabetes. It is used in addition to appropriate diet and exercise.

Trulicity is used:

- on its own when use of metformin (another medicine for type 2 diabetes) is not recommended;

- as an ‘add-on’ to other diabetes medicines.

Trulicity contains the active substance dulaglutide.

This EPAR was last updated on 16/03/2023

Authorisation details

Product details
Agency product number
Active substance
International non-proprietary name (INN) or common name
Therapeutic area (MeSH)
Diabetes Mellitus, Type 2
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Eli Lilly Nederland B.V.
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Papendorpseweg 83
3528 BJ Utrecht
The Netherlands

Product information

06/03/2023 Trulicity - EMEA/H/C/002825 - II/0065

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

  • Drugs used in diabetes

  • Blood glucose lowering drugs, excl. insulins

Therapeutic indication

Trulicity is indicated for the treatment of patients 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise

  • as monotherapy when metformin is considered inappropriate due to intolerance or contraindications
  • in addition to other medicinal products for the treatment of diabetes.

For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.

Assessment history

Changes since initial authorisation of medicine

Related content

How useful was this page?

Add your rating
1 rating
1 rating
1 rating
1 rating
3 ratings